Dirk Nagorsen

Person

Munich, DE

People

Patents Grantslast 30 patents

Information Patent Grant
Prevention of adverse effects caused by CD3 specific binding domains
- Patent number 11,633,408
- Issue date Apr 25, 2023
- Amgen Research (Munich) GmbH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Dosage regimen for administering a CD19xCD3 bispecific antibody to...
- Patent number 11,579,142
- Issue date Feb 14, 2023
- Amgen Research (Munich) GmbH
- Dirk Nagorsen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-leukocyte adhesion for the mitigation of potential adverse eve...
- Patent number 11,084,876
- Issue date Aug 10, 2021
- Amgen Research (Munich) GmbH
- Peter Kufer
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Means and methods for treating DLBCL
- Patent number 10,696,744
- Issue date Jun 30, 2020
- Amgen Research (Munich) GmbH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Dosage regimen for administering a CD19XCD3 bispecific antibody
- Patent number 10,662,243
- Issue date May 26, 2020
- Amgen Research (Munich) GmbH
- Dirk Nagorsen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Dosage regimen for administrating a CD19×CD3 bispecific antibody to...
- Patent number 10,191,034
- Issue date Jan 29, 2019
- Amgen Research (Munich) GmbH
- Dirk Nagorsen
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Prevention of adverse effects caused by CD3 specific binding domains
- Patent number 10,130,638
- Issue date Nov 20, 2018
- Amgen Research (Munich) GmbH
- Gerhard Zugmaier
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-leukocyte adhesion for the mitigation of potential adverse eve...
- Patent number 9,688,760
- Issue date Jun 27, 2017
- Amgen Research (Munich) GmbH
- Peter Kufer
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
PPS for the prevention of potential adverse effects caused by CD3 s...
- Patent number 9,486,475
- Issue date Nov 8, 2016
- Amgen Research (Munich) GmbH
- Peter Kufer
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Means and methods for treating DLBCL
- Patent number 9,192,665
- Issue date Nov 24, 2015
- Amgen Research (Munich) GmbH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Dosage regimen for administering a CD19XCD3 bispecific antibody
- Patent number 8,840,888
- Issue date Sep 23, 2014
- Micromet AG
- Dirk Nagorsen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO...
- Publication number 20190293635
- Publication date Sep 26, 2019
- AMGEN RESEARCH (MUNICH) GMBH
- Dirk Nagorsen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS
- Publication number 20190142846
- Publication date May 16, 2019
- AMGEN RESEARCH (MUNICH) GMBH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Eve...
- Publication number 20170327581
- Publication date Nov 16, 2017
- AMGEN RESEARCH (MUNICH) GMBH
- Peter Kufer
- G01 - MEASURING TESTING
Information Patent Application
MEANS AND METHODS FOR TREATING DLBCL
- Publication number 20160208001
- Publication date Jul 21, 2016
- AMGEN RESEARCH (MUNICH) GMBH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY
- Publication number 20150071928
- Publication date Mar 12, 2015
- AMGEN RESEARCH (MUNICH) GMBH
- Dirk Nagorsen
- G01 - MEASURING TESTING
Information Patent Application
PPS for the prevention of potential adverse effects caused by CD3 s...
- Publication number 20140228316
- Publication date Aug 14, 2014
- AMGEN RESEARCH (MUNICH) GMBH
- Peter Kufer
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Eve...
- Publication number 20140227272
- Publication date Aug 14, 2014
- AMGEN RESEARCH (MUNICH) GMBH
- Peter Kufer
- G01 - MEASURING TESTING
Information Patent Application
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO...
- Publication number 20140199307
- Publication date Jul 17, 2014
- AMGEN RESEARCH (MUNICH) GMBH
- Dirk Nagorsen
- G01 - MEASURING TESTING
Information Patent Application
Prevention of Adverse Effects Caused by CD3 Specific Binding Domains
- Publication number 20130287774
- Publication date Oct 31, 2013
- AMGEN RESEARCH (MUNICH) GMBH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MEANS AND METHODS FOR TREATING DLBCL
- Publication number 20130287778
- Publication date Oct 31, 2013
- AMGEN RESEARCH (MUNICH) GMBH
- Gerhard Zugmaier
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY
- Publication number 20120328618
- Publication date Dec 27, 2012
- Micromet AG
- Dirk Nagorsen
- G01 - MEASURING TESTING

Dirk Nagorsen

Person

Patents Grantslast 30 patents

Prevention of adverse effects caused by CD3 specific binding domains

Dosage regimen for administering a CD19xCD3 bispecific antibody to...

Anti-leukocyte adhesion for the mitigation of potential adverse eve...

Means and methods for treating DLBCL

Dosage regimen for administering a CD19XCD3 bispecific antibody

Dosage regimen for administrating a CD19×CD3 bispecific antibody to...

Prevention of adverse effects caused by CD3 specific binding domains

Anti-leukocyte adhesion for the mitigation of potential adverse eve...

PPS for the prevention of potential adverse effects caused by CD3 s...

Means and methods for treating DLBCL

Dosage regimen for administering a CD19XCD3 bispecific antibody

Patents Applicationslast 30 patents

DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO...

PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS

Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Eve...

MEANS AND METHODS FOR TREATING DLBCL

DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY

PPS for the prevention of potential adverse effects caused by CD3 s...

Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Eve...

DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO...

Prevention of Adverse Effects Caused by CD3 Specific Binding Domains

MEANS AND METHODS FOR TREATING DLBCL

DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY